Skip to main content
. 2025 Jun 19;15:1623241. doi: 10.3389/fcimb.2025.1623241

Table 2.

Antimicrobial drug susceptibility profiles for the 17 VIM-1–IMP-45–CRPA strains from China*.

Strains MIC (μg/mL)
MEM IMP CAZ TCC FEP AZT AK TOB LEV CIP P/T CZA COL SCF FDC
CJ01 >16 >16 >64 >128 >32 >32 >64 >16 >8 >4 >128/4 >128/4 ≤0.5 >64 0.5
CJ02 >16 >16 >64 >128 >32 >32 >64 >16 >8 >4 >128/4 >128/4 ≤0.5 >64 0.5
CJ03 >16 >16 >64 >128 >32 >32 >64 >16 >8 >4 >128/4 >128/4 ≤0.5 >64 0.5
CJ04 >16 >16 >64 >128 >32 2 >64 >16 >8 >4 >128/4 >128/4 ≤0.5 >64 1
CJ05 >16 >16 >64 >128 >32 >32 >64 >16 >8 >4 >128/4 >128/4 ≤0.5 >64 0.25
CJ06 >16 >16 >64 >128 >32 >32 >64 >16 >8 >4 >128/4 >128/4 ≤0.5 >64 0.125
CJ07 >16 >16 >64 >128 >32 >32 >64 >16 >8 >4 >128/4 >128/4 ≤0.5 >64 0.5
CJ08 >16 >16 >64 >128 >32 >32 >64 >16 >8 >4 >128/4 >128/4 ≤0.5 >64 0.5
CJ09 >16 >16 >64 >128 >32 >32 >64 >16 >8 >4 >128/4 >128/4 ≤0.5 >64 0.5
CJ10 >16 >16 >64 >128 >32 >32 >64 >16 >8 >4 >128/4 >128/4 ≤0.5 >64 0.5
CJ11 >16 >16 >64 >128 >32 >32 >64 >16 >8 >4 >128/4 >128/4 ≤0.5 >64 0.5
CJ12 >16 >16 >64 >128 >32 >32 >64 >16 >8 >4 >128/4 >128/4 ≤0.5 >64 0.06
CJ13 >16 >16 >64 >128 >32 16 >64 >16 >8 >4 64/4 >128/4 ≤0.5 >64 0.125
CJ14 >16 >16 >64 >128 >32 >32 >64 >16 >8 >4 >128/4 >128/4 ≤0.5 >64 0.5
CJ15 >16 >16 >64 >128 >32 >32 >64 >16 >8 >4 >128/4 >128/4 ≤0.5 >64 0.5
CJ16 >16 >16 >64 >128 >32 >32 >64 >16 >8 >4 >128/4 >128/4 ≤0.5 >64 0.5
CJ17 >16 >16 >64 >128 >32 >32 >64 >16 >8 >4 >128/4 >128/4 ≤0.5 >64 0.5
ATCC 27853 0.5 2 2 16 2 2 ≤2 ≤1 1 0.5 1/4 0.5/4 2 ≤8 0.125

* AK, amikacin; ATCC, American Type Culture Collection (https://www.atcc.org); AZT, aztreonam; CAZ, ceftazidime; CIP, ciprofloxacin; COL, colistin; CRPA, carbapenem-resistant Pseudomonas aeruginosa; CZA, ceftazidime/avibactam; FDC, cefiderocol; FEP, cefepime; IPM, imipenem; VIM, Verona integron-encoded metallo-β-lactamase; LEV, levofloxacin; MEM, meropenem; NA, not applicable; P/T, piperacillin/tazobactam; ST313, sequence type 313;SCF,cefoperazone/sulbactam; TOB, tobramycin; TCC, ticarcillin/clavulanic acid.